Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to $7.6 million.

  • Viemed Healthcare's Capital Expenditures fell 3059.44% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.1 million, marking a year-over-year increase of 2716.83%. This contributed to the annual value of $37.8 million for FY2024, which is 4475.53% up from last year.
  • According to the latest figures from Q3 2025, Viemed Healthcare's Capital Expenditures is $7.6 million, which was down 3059.44% from $8.1 million recorded in Q2 2025.
  • Viemed Healthcare's Capital Expenditures' 5-year high stood at $15.5 million during Q1 2025, with a 5-year trough of $1.8 million in Q1 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $7.0 million (2022), whereas its average is $7.3 million.
  • Examining YoY changes over the last 5 years, Viemed Healthcare's Capital Expenditures showed a top increase of 22456.57% in 2021 and a maximum decrease of 5741.71% in 2021.
  • Quarter analysis of 5 years shows Viemed Healthcare's Capital Expenditures stood at $6.7 million in 2021, then decreased by 16.37% to $5.6 million in 2022, then soared by 42.35% to $7.9 million in 2023, then soared by 49.13% to $11.8 million in 2024, then plummeted by 35.45% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $8.1 million for Q2 2025, and $15.5 million during Q1 2025.